Literature DB >> 28289500

Olmesartan-Induced Enteropathy.

Abimbola Adike1, Juan Corral2, David Rybnicek3, Daniel Sussman2, Samir Shah3, Eamonn Quigley1.   

Abstract

Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are villous atrophy and increased intraepithelial lymphocytes. Clinical presentation of olmesartan-induced enteropathy includes diarrhea, weight loss, and nausea. In contrast to celiac disease, tissue transglutaminase is not elevated and there is no response to a gluten-free diet. Including this entity in the differential diagnosis of sprue-like enteropathy is critical for its early diagnosis since replacing olmesartan with an alternative antihypertensive drug can simplify the diagnostic workup and provide both clinical and histologic improvement.

Entities:  

Keywords:  celiac disease; diarrhea; olmesartan-induced enteropathy

Mesh:

Substances:

Year:  2016        PMID: 28289500      PMCID: PMC5344475          DOI: 10.14797/mdcj-12-4-230

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  3 in total

1.  Severe spruelike enteropathy associated with olmesartan.

Authors:  Alberto Rubio-Tapia; Margot L Herman; Jonas F Ludvigsson; Darlene G Kelly; Thomas F Mangan; Tsung-Teh Wu; Joseph A Murray
Journal:  Mayo Clin Proc       Date:  2012-06-22       Impact factor: 7.616

Review 2.  Systematic review: Sprue-like enteropathy associated with olmesartan.

Authors:  G Ianiro; S Bibbò; M Montalto; R Ricci; A Gasbarrini; G Cammarota
Journal:  Aliment Pharmacol Ther       Date:  2014-05-07       Impact factor: 8.171

3.  Olmesartan-associated enteropathy: results of a national survey.

Authors:  L Marthey; G Cadiot; P Seksik; P Pouderoux; J Lacroute; F Skinazi; B Mesnard; J A Chayvialle; G Savoye; A Druez; D Parlier; V Abitbol; M Gompel; M Eoche; E Poncin; R Bobichon; P Colardelle; P Wils; H Salloum; S Peschard; F Zerbib; B Méresse; N Cerf-Bensussan; G Malamut; F Carbonnel
Journal:  Aliment Pharmacol Ther       Date:  2014-09-09       Impact factor: 8.171

  3 in total
  8 in total

Review 1.  Association of sprue-like enteropathy and angiotensin receptor-1 antagonists.

Authors:  René R Wenzel; Christian Datz
Journal:  Wien Klin Wochenschr       Date:  2019-08-30       Impact factor: 1.704

2.  Olmesartan: A Little-Known Cause of Diarrhoea.

Authors:  Joana Serôdio; Joana Carneiro; Manuel Veiga; António Ferreira
Journal:  Eur J Case Rep Intern Med       Date:  2019-06-28

3.  Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case Report.

Authors:  Andromachi Makri; Matilda Florentin; Moses S Elisaf; George Liamis
Journal:  Curr Drug Saf       Date:  2019

4.  [Chronic diarrhea with easy solution, about 3 cases].

Authors:  Alba Nadal-Máñez; Rosa Casañ-Fernández; Francisco Javier Sanz-Gallur; Maria Gràcia Cardona-Rovira
Journal:  Aten Primaria       Date:  2019-01-04       Impact factor: 1.137

5.  A case report of olmesartan-associated sprue-like enteropathy: Diagnosis and healing confirmed by capsule endoscopy.

Authors:  Yoshiharu Yamaguchi; Takahiro Miwa; Ryo Murakami; Akane Sugimura; Kazuhiro Yamamoto; Tomoya Sugiyama; Yasuhiro Tamura; Shinya Izawa; Masahide Ebi; Yasushi Funaki; Naotaka Ogasawara; Makoto Sasaki; Kunio Kasugai
Journal:  DEN open       Date:  2022-06-18

6.  Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy.

Authors:  Peter Malfertheiner; Claudio Ripellino; Nazarena Cataldo
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-02-19       Impact factor: 2.890

7.  Olmesartan Associated Enteropathy: A Rare Underdiagnosed Cause of Diarrhea and Weight Loss.

Authors:  Sripriya Gonakoti; Sanjiv Khullar; Aarthi Rajkumar
Journal:  Am J Case Rep       Date:  2019-01-26

8.  A Case Report of Olmesartan-Induced Enteropathy.

Authors:  Benjamin S Daines; Alfred Kankam; Sadia Tanami; Rajesh Nambiar
Journal:  Cureus       Date:  2021-12-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.